Literature DB >> 23919827

Clinical and genetic characteristics of Chinese patients with hereditary haemorrhagic telangiectasia-associated pulmonary hypertension.

Yan-Jun Chen1, Qing-Hui Yang, Dong Liu, Qian-Qian Liu, Mélanie Eyries, Liang Wen, Wen-Hui Wu, Xin Jiang, Ping Yuan, Rui Zhang, Florent Soubrier, Zhi-Cheng Jing.   

Abstract

BACKGROUND: Mutations in activin receptor-like kinase-1 (ACVRL-1) or endoglin (ENG) are mostly identified in patients with hereditary haemorrhagic telangiectasia (HHT) associated with pulmonary hypertension (PH), but have not yet been studied in Chinese patients.
MATERIAL AND METHODS: In this study, we investigated the clinical and molecular genetic features of Chinese patients with HHT-associated PH and analysed genotype/phenotype correlations in 14 probands and their relatives. Mutation analyses in ACVRL-1, bone morphogenetic protein receptor type 2 (BMPR2) and ENG were performed in 14 Chinese Han patients with HHT-associated PH.
RESULTS: The overall mutation rate was 71·4%, including 8 ACVRL-1 mutations and 2 ENG mutations, 6 of which were novel. Six patients were identified with arteriovenous malformations (AVMs), including four patients with pulmonary AVMs and two patients with liver AVMs. Five of the patients with AVMs were identified with mutations. Most patients received targeted therapy for PH.
CONCLUSIONS: Our findings have revealed the clinical phenotype and molecular genetic features of HHT-associated PH in Chinese Han patients and indicate that mutations of ACVRL-1 and ENG are genetic predisposing factors in Chinese patients. Our data further addressed clinical management and have provided limited experience in treating this group of disorders.
© 2013 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  ACVRL-1; ENG; gene mutations; hereditary haemorrhagic telangiectasia; pulmonary hypertension

Mesh:

Substances:

Year:  2013        PMID: 23919827     DOI: 10.1111/eci.12138

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  9 in total

Review 1.  Epidemiology of pulmonary arterial hypertension.

Authors:  Xin Jiang; Zhi-Cheng Jing
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

2.  Genetic Mutation Analysis Can Supplement Clinically Confirmed Hereditary Hemorrhagic Telangiectasia Populations.

Authors:  Seon Tae Kim
Journal:  Clin Exp Otorhinolaryngol       Date:  2019-10-02       Impact factor: 3.372

3.  Pulmonary Hypertension and Hereditary Hemorrhagic Telangiectasia Related to an ACVRL1 Mutation.

Authors:  Tetsuro Yokokawa; Koichi Sugimoto; Yusuke Kimishima; Tomofumi Misaka; Akiomi Yoshihisa; Hiroko Morisaki; Osamu Yamada; Kazuhiko Nakazato; Takafumi Ishida; Yasuchika Takeishi
Journal:  Intern Med       Date:  2019-09-11       Impact factor: 1.271

4.  Variant analysis in Chinese families with hereditary hemorrhagic telangiectasia.

Authors:  Yali Zhao; Yuan Zhang; Xiangdong Wang; Luo Zhang
Journal:  Mol Genet Genomic Med       Date:  2019-08-10       Impact factor: 2.183

5.  Clinical characteristics and prognosis analysis of idiopathic and hereditary pulmonary hypertension patients with ACVRL1 gene mutations.

Authors:  Xinyu Zhang; Chen Zhang; Qiangqiang Li; Chunmei Piao; Hongsheng Zhang; Hong Gu
Journal:  Pulm Circ       Date:  2021-10-14       Impact factor: 3.017

Review 6.  Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects.

Authors:  Rajiv D Machado; Laura Southgate; Christina A Eichstaedt; Micheala A Aldred; Eric D Austin; D Hunter Best; Wendy K Chung; Nicola Benjamin; C Gregory Elliott; Mélanie Eyries; Christine Fischer; Stefan Gräf; Katrin Hinderhofer; Marc Humbert; Steven B Keiles; James E Loyd; Nicholas W Morrell; John H Newman; Florent Soubrier; Richard C Trembath; Rebecca Rodríguez Viales; Ekkehard Grünig
Journal:  Hum Mutat       Date:  2015-10-12       Impact factor: 4.878

7.  NAPG mutation in family members with hereditary hemorrhagic telangiectasia in China.

Authors:  Yu Xu; Yong-Biao Zhang; Li-Jun Liang; Jia-Li Tian; Jin-Ming Lin; Pan-Pan Wang; Rong-Hui Li; Ming-Liang Gu; Zhan-Cheng Gao
Journal:  BMC Pulm Med       Date:  2021-06-10       Impact factor: 3.317

8.  Pulmonary hypertension subtypes associated with hereditary haemorrhagic telangiectasia: Haemodynamic profiles and survival probability.

Authors:  Sabine Revuz; Evelyne Decullier; Isabelle Ginon; Nicolas Lamblin; Pierre-Yves Hatron; Pierre Kaminsky; Marie-France Carette; Pascal Lacombe; Anne-Claire Simon; Sophie Rivière; Jean-Robert Harlé; Alain Fraisse; Christian Lavigne; Vanessa Leguy-Seguin; Ari Chaouat; Chahera Khouatra; Sophie Dupuis-Girod; Eric Hachulla
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

Review 9.  Pulmonary Arterial Hypertension and Hereditary Haemorrhagic Telangiectasia.

Authors:  Veronique M M Vorselaars; Anna E Hosman; Cornelis J J Westermann; Repke J Snijder; Johannes J Mager; Marie-Jose Goumans; Marco C Post
Journal:  Int J Mol Sci       Date:  2018-10-17       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.